The Company is a specialty pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products focused on two therapeutic categories: women's healthcare and dermatology.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I can't imagine how Moody's affirmed WCRX's credit ratings to complete the PG Pharma purchase. They borrowed the entire amount to finance the deal, and it increased the company's debt from $800 million to $3.9 billion. I understand that the acquisition is "accretive", but they are on the clock to deliver new products when their existing patents expire in a few short years. WCRX is going to be busy servicing debt for a long time, and somewhere in their budget they better plan to do the R&D necessary to take their business forward.
I would estimate that they've bitten off more than they can safely chew.